MONTREAL — An open-label extension study of subcutaneous efgartigimod PH20 to treat chronic inflammatory demyelinating polyneuropathy (CIDP) showed durability of functional improvements to week 24, with no new safety signals. As reported by Medscape Medical News, the US Food and Drug Administration (FDA) recently approved the coformulation of efgartigimod alfa and hyaluronidase-qvfc (VYVGART Hytrulo…
